Research and development expenses for the fourth quarter increased by 27% to $1.3 million, while general and administrative expenses decreased by 26% to $1.5 million. The company reported a net gain of $2.2 million for the quarter, contrasting sharply with a net loss of $3.4 million in the same quarter of 2024. For the full year, HCW Biologics recorded a net loss of $6.5 million, down from a loss of $30 million in 2024, indicating improved financial management despite the revenue decline.
The company also highlighted its ongoing clinical trials, including the first-in-human trial for HCW9302, aimed at treating autoimmune disorders. Dr. Hing C. Wong, the CEO, expressed optimism about the potential of HCW9302 to activate regulatory T cells and suppress autoimmune responses, which could significantly impact the treatment landscape for conditions like alopecia areata.
Despite the challenges faced in 2025, HCW Biologics remains focused on its strategic goals, including the commercialization of its proprietary compounds and the advancement of its clinical programs. The company is also navigating compliance issues with Nasdaq, having received a notice regarding its stock price not maintaining the minimum bid requirement. HCW Biologics plans to appeal this determination, aiming to secure its position in the market as it continues to develop innovative treatments for chronic inflammatory diseases.
